Immunomedics (IMMU) Stock Rating Lowered by BidaskClub

BidaskClub lowered shares of Immunomedics (NASDAQ:IMMU) from a strong-buy rating to a buy rating in a report issued on Thursday, BidAskClub reports.

A number of other brokerages have also recently commented on IMMU. Zacks Investment Research upgraded shares of Immunomedics from a sell rating to a hold rating in a report on Thursday, January 10th. HC Wainwright set a $28.00 target price on shares of Immunomedics and gave the company a buy rating in a report on Tuesday, April 2nd. Cowen restated a buy rating and set a $30.00 target price on shares of Immunomedics in a report on Friday, January 18th. Jefferies Financial Group set a $21.00 target price on shares of Immunomedics and gave the company a buy rating in a report on Friday, January 18th. Finally, B. Riley started coverage on shares of Immunomedics in a report on Tuesday, January 8th. They set a buy rating and a $55.00 target price on the stock. One research analyst has rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Immunomedics currently has an average rating of Buy and a consensus target price of $28.45.

NASDAQ:IMMU opened at $16.99 on Thursday. Immunomedics has a twelve month low of $11.55 and a twelve month high of $27.33. The company has a debt-to-equity ratio of 0.06, a quick ratio of 13.45 and a current ratio of 13.45.

Immunomedics (NASDAQ:IMMU) last announced its earnings results on Monday, February 25th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.16). On average, research analysts predict that Immunomedics will post -1.38 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the company. Exane Derivatives purchased a new position in shares of Immunomedics in the 4th quarter worth about $32,000. Karp Capital Management Corp purchased a new position in shares of Immunomedics in the 4th quarter worth about $33,000. North Star Investment Management Corp. purchased a new position in shares of Immunomedics in the 4th quarter worth about $50,000. Pearl River Capital LLC purchased a new position in shares of Immunomedics in the 4th quarter worth about $66,000. Finally, Amundi Pioneer Asset Management Inc. purchased a new position in shares of Immunomedics in the 4th quarter worth about $84,000. Hedge funds and other institutional investors own 85.22% of the company’s stock.

Immunomedics Company Profile

Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.

Further Reading: Google Finance Portfolio

Analyst Recommendations for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.